The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2023 | Blood group genotyping program to improve transfusion outcomes in hemoglobinopathies
Sara Trompeter, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the implementation of the Sickle Cell and Thalassemia Blood Group Genotyping Program into healthcare systems. Sponsored by NHS England, this program encourages patients with sickle cell disease (SCD), thalassemia, and rare inherited anemia to participate, in order to enhance donor compatibility for improved transfusion outcomes. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
